Safety and Efficacy of Brolucizumab in DME Backed by 3 Studies

Three recent clinical trials have found Brolucizumab 6 mg to have a positive benefit-risk ratio for treating diabetic macular edema. In the KESTREL and KITE studies, both phase 3 double-masked multicenter trials, Novartis’s brolucizumab demonstrated noninferiority to aflibercept, which is currently approved for the condition. Results were similar in the KINGFISHER trial.

According to Michael Ip, MD, in Healio, “In the KINGFISHER trial, brolucizumab met the primary endpoint of noninferiority to aflibercept in change in best corrected visual acuity from baseline through week 52 when dosed every 4 weeks.”

Find out more about the trials by clicking here.

(Source: Helio, February 7^th, 2022)